Skip to main content

Table 3 A comparison of the clinical and laboratory characteristics of patients with histologic BMI (BMI histo + ) with normal karyotypes and patients with chromosomal abnormalities

From: Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement

Parameters

BMIhisto+and normal karyotype

Abnormal karyotypes

(n = 135)

1 numerical

1 structural

≥ 2 abnormalities

  

(n = 42)

(n = 12)

(n = 138)

Age (years)

    

  Median (range)

58 (2–86)

67 (11–83) *

56 (45–77)

60 (10–86)

  Age > 60 yr

64/135 (47.4)

34/42 (81.0) *

5/12 (41.7)

66/138 (47.8)

Gender (male/female)

59/76 (43.7)

35/7 (83.3) *

10/2 (83.3) *

76/62 (55.1)

ECOG ≥ 2

26/135 (19.3)

6/42 (14.3)

0/12 (0)

62/138 (44.9) *

High serum LDH

95/135 (70.4)

16/42 (38.1) *

6/12 (50.0)

123/138 (89.1) *

B symptoms

50/135 (37.0)

7/42 (16.7) *

6/12 (50.0)

98/138 (71.0) *

Stage 3 or 4,

123/135 (91.1)

18/42 (42.9) *

9/12 (75.0)

126/138 (91.3)

excluding BM status

    

Extranodal ≥ 2 sites

89/135 (65.9)

13/42 (31.0) *

5/12 (41.7)

112/138 (81.2) *

IPI risk

    

  Low

0/135 (0)

16/42 (38.1)

1/12 (8.3)

1/138 (0.7)

  Low/intermediate

28/135 (20.7)

10/42 (23.8)

5/12 (41.7)

4/138 (2.9)

  High/intermediate

65/135 (48.2)

10/42 (23.8)

6/12 (50.0)

58/138 (42.0)

  High

42/135 (31.1)

6/42 (14.3) *

0/12 (0) *

75/138 (54.4) *

Non-GCB type

46/73 (63.0)

17/26 (65.4)

3/8 (37.5)

53/88 (60.2)

CD5- positive

4/32 (12.5)

0/3 (0)

0/1 (0)

3/30 (10.0)

R-CHOP treatment

83/135 (61.5)

31/42 (73.8)

8/12 (66.7)

78/138 (56.5)

Death

53/135 (39.3)

10/42 (23.8)

2/12 (16.7)

90/138 (65.2) *

  1. *Significant P value (< 0.05) for each subgroup compared with the group of BMIhisto+ patients with normal karyotypes.
  2. The data represent the number (percentage) for categorical variables, unless otherwise indicated.
  3. Abbreviations: DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell-like; IPI, International Prognostic Index; LDH, lactic dehydrogenase; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.